as suggested for the phenylalanine benzyl esters [12], perhaps by partitioning into the membrane and destabilising the transporters, the much reduced effect of its isoform, para-vanillin (or usually simply vanillin) argues against this. 5HMF, currently in clinical trials in SCD patients, was different in effect, at least in the transport assays carried out in this work. Nevertheless, present findings indicate that it is possible to design aromatic aldehydes which combine a direct inhibitory effect on HbS polymerisation together with favourable effects on reduction of RBC permeability to thereby increase RBC hydration. These dual effects may potentiate their ability to ameliorate the complications of SCD.